Low Dose Aspirin Inhibition of COX-2 Derived PGE2 in Male Smokers
Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
Regular aspirin use has been associated with a reduction in the development of a number of
different malignancies including lung cancer. The mechanism of aspirin's cancer prevention is
not known. This study will evaluate whether once daily aspirin use can reduce the production
of a protein named prostaglandin E2 (PGE-2), which is known to promote cancer. Specifically,
this study will evaluate if aspirin can inhibit the production of PGE-2 by blocking an enzyme
named cycloxygenase-2 (COX-2). To accomplish these goals, participants will take either
aspirin 325 mg daily, celecoxib 200 mg twice daily, or the combination of both during various
days of this 16-day study. Urine be collected to evaluate for PGE-2 production at 4
timepoints in this 16-day study.